BIRC5 and acute myeloid leukemia: Collectively, these results indicated that inhibiting Sp1 and c-Myc-dependent survivin expression could cause chemo-sensitization in LSCs, suggesting that survivin could be an effective target for further clinical applications for AML treatment.